483
Novartis Pharma AGNovartis Pharma AG – FDA 483, Aug 30, 2022
Record Details
Novartis Pharma AG, a drug substance manufacturer in Basel, Switzerland, received three observations during an FDA inspection. The inspection identified deficiencies related to inadequate controls for computerized systems, insufficient qualification of equipment used for stability sample storage, and a lack of adequate reserve samples for quality control analysis. These findings highlight concerns with data integrity, equipment validation, and quality control procedures at the facility.
View Company Profile
ID · 7020c2fe-862b-4517-b28a-f6b34cd39f2d
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.